The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: Epidemiology and risk factors

Annals of Internal Medicine

Volumn 125, Issue 6, 1996, Pages 465-470

  Gordon, Steven M ^a   Carlyn, Cynthia J ^a,b   Doyle, Laura J ^a   Knapp, Cynthia C ^a   Longworth, David L ^a   Hall, Geraldine S ^a   Washington, John A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Cleveland Clinic Foundation ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN;

ARTICLE; CASE CONTROL STUDY; DRUG EFFECT; GENETICS; GENOTYPE; GONORRHEA; HUMAN; MALE; MICROBIOLOGY; NEISSERIA GONORRHOEAE; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; UNITED STATES; URETHRITIS;

ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; CIPROFLOXACIN; ELECTROPHORESIS, GEL, PULSED-FIELD; GENOTYPE; GONORRHEA; HUMANS; MALE; NEISSERIA GONORRHOEAE; OHIO; RISK FACTORS; URETHRITIS;

EID: 0030587264     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-6-199609150-00006     Document Type: Article

References (21)

1. Antibiotic-resistant strains of Neisseria gonorrhoeae. Policy guidelines for detection, management, and control. MMWR Morb Mortal Wkly Rep. 1987;36(Suppl 5):1S-8S.
2. 1993 sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep. 1993;42(RR-14):1-102.
3. Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolones - Ohio and Hawaii, 1992-1994. MMWR Morb Mortal Wkly Rep. 1994;43:325-7.
4. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing - Fifth Informational Supplement. Villanova, PA: National Committee for Clinical Laboratory Standards; 1994: Document M100-55.
5. Yeung KH, Dillon JR. Norfloxacin resistant Neisseria gonorrhoeae in North America [Letter]. Lancet. 1990;336:759.
6. Gorwitz PJ, Nakashima AK, Moran JS, Knapp JS. Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae - United States, 1988-1991. The Gonococcal Isolate Surveillance Project Study Group. MMWR CDC Surveill Summ. 1993;42:29-39.
7. Knapp JS, Washington JA, Doyle U, Neal SW, Parekh MC, Rice RJ. Persistence of Neisseria gonorrhoeae strains with decreased susceptibilities to ciprofloxacin and ofloxacin in Cleveland, Ohio, from 1992 through 1993. Antimicrob Agents Chemother. 1994;38:2194-6.
8. Carlyn CJ, Doyle U, Knapp CC, Ludwig MD, Washington JA. Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin. Antimicrob Agents Chemother. 1995;39:1606-8.
9. Morell JA, Janda WM, Doern GV. Neisseria and Branhamella. In: Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of Clinical Microbiology. 5th ed. Washington, DC: American Society for Microbiology; 1991:248-76.
10. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 3rd ed. Villanova, PA: National Committee for Clinical Laboratory Standards; 1993: Document M7-A3.
11. Knapp JS, Hale JA, Neal SW, Wintersheid K, Rice RJ, Whittington WL. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin. Antimicrob Agents Chemother. 1995;39:2442-5.
12. Xia M, Whittington WL, Holmes KK, Plummer FA, Roberts MC. Pulsed-field gel electrophoresis for genomic analysis of Neisseria gonorrhoeae. J Infect Dis. 1995;171:455-8.
13. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacteria strain typing. J Clin Microbiol. 1995;33:2233-9.
14. Fluoroquinolone resistance in Neisseria gonorrhoeae - Colorado and Washington, 1995. MMWR Morb Mortal Wkly Rep. 1995;44:761-4.
15. Richard P, Delangle MH, Merrien D, Barille S, Reynaud A, Minozzi C, et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis. 1994;19:54-9.
16. Gordon SM, Mosure DJ, Lewis J, Brown S. McNagny SE, Schmid GP. Prevalence of self-medication with antibiotics among patients attending a clinic for treatment of sexually transmitted diseases. Clin Infect Dis. 1993;17:462-5.
17. Tartaglione TA, Russo ME. Pharmacology of drugs used in venereology. In: Holmes KK, Mardh PA. Sparlling PF, Weisner PJ, eds. Sexually Transmitted Diseases: Past. Present, and Future. 2d ed. New York: McGraw-Hill; 1990:993-1019.
18. Tapsall JW, Shultz TR, Lovett R, Munro R. Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea [Letter]. Med J Aust. 1992;156:143.
19. Birley H, McDonald P, Carey P, Fletcher J. High level ciprofloxacin resistance in Neisseria gonorrhoeae [Letter]. Genitourin Med. 1994;70:292-3.
20. Kam KM, Lo KK, Ho NK, Cheung MM. Rapid decline in penicillinase-producing Neisseria gonorrhoeae in Hong Kong associated with emerging 4-fluoroquinolone resistance. Genitourin Med. 1995;71:141-4.
21. Jephcott AE, Turner A. Ciprofloxacin resistance in gonococci [Letter]. Lancet. 1990;335:165.